Desensitization and management of allograft rejection.

Journal Article (Journal Article;Review)

PURPOSE OF REVIEW: Chronic lung allograft dysfunction (CLAD) limits the success of lung transplantation. Among the risk factors associated with CLAD, we recognize pretransplant circulating antibodies against the human leukocyte antigens (HLA), acute cellular rejection (ACR) and antibody-mediated rejection (AMR). This review will summarize current data surrounding management of desensitization, ACR, AMR, and CLAD. RECENT FINDINGS: Strategies in managing in highly sensitized patients waiting for lung transplant include avoidance of specific HLA antigens and reduction of circulating anti-HLA antibodies at time of transplant. Several multimodal approaches have been studied in the treatment of AMR with a goal to clear circulating donor-specific antibodies (DSAs) and to halt the production of new antibodies. Different immunosuppressive strategies focus on influence of the host immune system, particularly T-cell responses, in order to prevent ACR and the progression of CLAD. SUMMARY: The lack of significant evidence and consensus limits to draw conclusion regarding the impact of specific immunosuppressive regimens in the management of HLA antibodies, ACR, and CLAD. Development of novel therapeutic agents and use of multicenter randomized clinical trials will allow to better define patient-specific treatments and improve the length and quality of life of lung transplant recipients.

Full Text

Duke Authors

Cited Authors

  • Zaffiri, L

Published Date

  • June 1, 2021

Published In

Volume / Issue

  • 26 / 3

Start / End Page

  • 314 - 320

PubMed ID

  • 33938468

Electronic International Standard Serial Number (EISSN)

  • 1531-7013

Digital Object Identifier (DOI)

  • 10.1097/MOT.0000000000000878


  • eng

Conference Location

  • United States